Histology | PD-L1 expression | EGFR mutation | Occurrence (Non-Asian) | Occurrence (Asian) | OS (Hazard ratio NMA) | PFS (Fractional polynomial NMA) |
---|---|---|---|---|---|---|
Non-squamous | <  5% | Negative | 32.8% | 21.2% | Docetaxel + nintedanib: 2.6 (0.1, 5.6) Docetaxel + ramucirumab: 2.3 (0.3, 4.6) | Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Squamous | <  5% | Negative | 21.0% | 20.2% | Nivolumab: 5.5 (0.7, 12.4) Docetaxel + ramucirumab: 2.0 (0.3, 4.0) | Nivolumab: 2.6 (0.0, 5.8)a Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Non-squamous | ≥ 5% | Negative | 20.5% | 13.3% | Nivolumab: 12.9 (5.6, 23.8) Docetaxel + nintedanib: 2.6 (0.1, 5.6) Docetaxel + ramucirumab: 2.3 (0.3, 4.6) | Nivolumab: 5.0 (2.2, 8.2) Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Squamous | ≥ 5% | Negative | 13.2% | 12.7% | Nivolumab 8.0 (1.6, 17.8) Docetaxel + ramucirumab: 2.0 (0.3, 4.0) | Nivolumab: 5.7 (1.8, 10.1) Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Non-squamous | <  5% | Positive | 7.2% | 18.8% | Docetaxel + erlotinib: 13.4 (4.8, 27.0) Erlotinib + pemetrexed: 8.0 (0.3, 28.5) Erlotinib: 7.4 (2.5, 14.9) Gefitinib: 4.4 (0.8, 10.5) Docetaxel + nintedanib: 2.6 (0.1, 5.6) Docetaxel + ramucirumab: 2.3 (0.3, 4.6) | Docetaxel + erlotinib: 8.1 (4.9, 10.9) Erlotinib + pemetrexed: 7.0 (1.2, 14.6) Erlotinib: 6.8 (3.4, 11.3) Gefitinib: 5.4 (2.7, 8.6) Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Squamous | <  5% | Positive | 0.5% | 1.3% | Docetaxel + erlotinib: 11.9 (4.2, 23.8) Erlotinib: 6.5 (2.2, 13.2) Nivolumab: 5.5 (0.7, 12.4) Gefitinib: 3.9 (0.7, 9.3) Docetaxel + ramucirumab: 2.0 (0.3, 4.0) | Docetaxel + erlotinib: 8.1 (4.9, 10.9) Erlotinib: 6.8 (3.4, 11.3) Gefitinib: 5.4 (2.7, 8.6) Nivolumab: 2.6 (0.0, 5.8)a Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Non-squamous | ≥ 5% | Positive | 4.5% | 11.8% | Docetaxel + erlotinib: 13.4 (4.8, 27.0) Nivolumab: 12.9 (5.6, 23.8) Erlotinib + pemetrexed: 8.0 (0.3, 28.5) Erlotinib: 7.4 (2.5, 14.9) Gefitinib: 4.4 (0.8, 10.5) Docetaxel + nintedanib: 2.6 (0.1, 5.6) Docetaxel + ramucirumab: 2.3 (0.3, 4.6) | Docetaxel + erlotinib: 8.1 (4.9, 10.9) Erlotinib + pemetrexed: 7.0 (1.2, 14.6) Erlotinib: 6.8 (3.4, 11.3) Gefitinib: 5.4 (2.7, 8.6) Nivolumab: 5.0 (2.2, 8.2) Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Squamous | ≥ 5% | Positive | 0.3% | 0.8% | Docetaxel + erlotinib: 11.9 (4.2, 23.8) Nivolumab 8.0 (1.6, 17.8) Erlotinib: 6.5 (2.2, 13.2) Gefitinib: 3.9 (0.7, 9.3) Docetaxel + ramucirumab: 2.0 (0.3, 4.0) | Docetaxel + erlotinib: 8.1 (4.9, 10.9) Erlotinib: 6.8 (3.4, 11.3) Nivolumab: 5.7 (1.8, 10.1) Gefitinib: 5.4 (2.7, 8.6) Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |